Literature DB >> 22265148

Clinical features of newly diagnosed cytomegalovirus retinitis in northern Thailand.

Somsanguan Ausayakhun1, Jeremy D Keenan, Sakarin Ausayakhun, Choeng Jirawison, Claire M Khouri, Alison H Skalet, David Heiden, Gary N Holland, Todd P Margolis.   

Abstract

PURPOSE: To characterize the clinical manifestations of cytomegalovirus (CMV) retinitis in northern Thailand.
DESIGN: Prospective, observational, cross-sectional study.
METHODS: We recorded characteristics of 52 consecutive patients newly diagnosed with CMV retinitis at a tertiary university-based medical center in northern Thailand. Indirect ophthalmoscopy by experienced ophthalmologists was supplemented with fundus photography to determine the proportion of eyes with various clinical features of CMV retinitis.
RESULTS: Of the 52 patients with CMV retinitis, 55.8% were female. All were HIV-positive. The vast majority (90.4%) had started antiretroviral therapy. CMV retinitis was bilateral in 46.2% of patients. Bilateral visual acuity worse than 20/60 was observed in 23.1% of patients. Of 76 eyes with CMV retinitis, 61.8% had zone I disease and 21.6% had lesions involving the fovea. Lesions larger than 25% of the retinal area were observed in 57.5% of affected eyes. CMV retinitis lesions commonly had marked or severe border opacity (47.4% of eyes). Vitreous haze often was present (46.1% of eyes). Visual impairment was more common in eyes with larger retinitis lesions. Retinitis lesion size, used as a proxy for duration of disease, was associated with fulminant appearance (odds ratio, 1.24; 95% confidence interval, 1.01 to 1.51) and marked or severe border opacity (odds ratio, 1.36; 95% confidence interval, 1.11 to 1.67). Based on lesion size, retinitis preceded antiretroviral treatment in each patient.
CONCLUSIONS: Patients seeking treatment at a tertiary medical center in northern Thailand had advanced CMV retinitis, possibly because of delayed diagnosis. Earlier screening and treatment of CMV retinitis may limit progression of disease and may prevent visual impairment in this population.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265148      PMCID: PMC3331920          DOI: 10.1016/j.ajo.2011.10.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  34 in total

Review 1.  Immune recovery uveitis.

Authors:  B D Kuppermann; G N Holland
Journal:  Am J Ophthalmol       Date:  2000-07       Impact factor: 5.258

2.  Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center.

Authors:  J Biswas; H N Madhavan; A E George; N Kumarasamy; S Solomon
Journal:  Am J Ophthalmol       Date:  2000-01       Impact factor: 5.258

3.  Ophthalmic involvement in acquired immunodeficiency syndrome.

Authors:  A G Palestine; M M Rodrigues; A M Macher; C C Chan; H C Lane; A S Fauci; H Masur; D Longo; C M Reichert; R Steis
Journal:  Ophthalmology       Date:  1984-09       Impact factor: 12.079

4.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.

Authors:  R B Nussenblatt; A G Palestine; C C Chan; F Roberge
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

5.  Dual infection of retina with human immunodeficiency virus type 1 and cytomegalovirus.

Authors:  P R Skolnik; R J Pomerantz; S M de la Monte; S F Lee; G D Hsiung; R Y Foos; G M Cowan; B R Kosloff; M S Hirsch; J S Pepose
Journal:  Am J Ophthalmol       Date:  1989-04-15       Impact factor: 5.258

6.  A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group.

Authors:  G N Holland; W C Buhles; B Mastre; H J Kaplan
Journal:  Arch Ophthalmol       Date:  1989-12

7.  Epidemiology of the ocular complications of HIV infection in Chiang Mai.

Authors:  Somsanguan Ausayakhun; Sopa Watananikorn; Nimitr Ittipunkul; Winai Chaidaroon; Prapatsorn Patikulsila; Direk Patikulsila
Journal:  J Med Assoc Thai       Date:  2003-05

8.  Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients.

Authors:  G N Holland; J D Shuler
Journal:  Arch Ophthalmol       Date:  1992-10

9.  Frosted branch angiitis associated with cytomegalovirus retinitis.

Authors:  R F Spaide; A T Vitale; I R Toth; J M Oliver
Journal:  Am J Ophthalmol       Date:  1992-05-15       Impact factor: 5.258

10.  Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus.

Authors:  P R Skolnik; B R Kosloff; M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

View more
  5 in total

1.  Retinal detachment associated with AIDS-related cytomegalovirus retinitis: risk factors in a resource-limited setting.

Authors:  Michael Yen; Jenny Chen; Somsanguan Ausayakhun; Paradee Kunavisarut; Pornpattana Vichitvejpaisal; Sakarin Ausayakhun; Choeng Jirawison; Jessica Shantha; Gary N Holland; David Heiden; Todd P Margolis; Jeremy D Keenan
Journal:  Am J Ophthalmol       Date:  2014-10-22       Impact factor: 5.258

2.  Patterns of cytomegalovirus retinitis at a tertiary referral center in Turkey.

Authors:  Muhammed Talha Sadik; Nihan Aksu Ceylan; Zafer Cebeci; Nur Kir; Merih Oray; Ilknur Tugal-Tutkun
Journal:  Int Ophthalmol       Date:  2021-04-22       Impact factor: 2.031

3.  Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.

Authors:  Ifeoma N Ude; Steven Yeh; Jessica G Shantha
Journal:  Ann Eye Sci       Date:  2022-03

4.  Telemedicine diagnosis of cytomegalovirus retinitis by nonophthalmologists.

Authors:  Michael Yen; Somsanguan Ausayakhun; Jenny Chen; Sakarin Ausayakhun; Choeng Jirawison; David Heiden; Gary N Holland; Todd P Margolis; Jeremy D Keenan
Journal:  JAMA Ophthalmol       Date:  2014-09       Impact factor: 7.389

5.  Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS.

Authors:  Gary N Holland; Mark L Van Natta; David T Goldenberg; Rory Ritts; Ronald P Danis; Douglas A Jabs
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.